Viatris Inc. Common Stock (VTRS) Stock Price

VTRSStockS&P 500

$18.66+84.70%52W

Market Cap$21.43B

P/E—

PEG Ratio3.17

Div yield5.09%

Beta0.89

VTRS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)24.21%

Price vs S&P 500 (4W)10.42%

PEG Ratio3.17

VGM Score66.09

Indicated Dividend Yield (Annual)5.09%

P/CF (Annual)9.25x

Book Value / Share (Quarterly)$12.34

P/TBV (Annual)9.50x

Indicated Dividend (Annual)$0.48

Revenue Growth (3Y)-4.20%

Cash Flow / Share (Quarterly)$1.57

Payout Ratio (TTM)79.14%

Price vs S&P 500 (YTD)37.91%

Gross Margin (TTM)40.34%

Net Profit Margin (TTM)-2.79%

EPS (TTM)$-0.36

10-Day Avg Trading Volume8.51M

EPS Excl Extra (TTM)$-0.36

Revenue Growth (5Y)3.66%

EPS (Annual)$-3.00

Dividend / Share (Annual)$0.48

ROI (Annual)-12.07%

Gross Margin (Annual)39.55%

Net Profit Margin (5Y Avg)-4.57%

Cash / Share (Quarterly)$1.18

Revenue Growth QoQ (YoY)4.88%

ROA (Last FY)-9.45%

Revenue Growth TTM (YoY)4.40%

EBITD / Share (TTM)$2.29

ROE (5Y Avg)-4.67%

Operating Margin (TTM)-0.91%

Cash Flow / Share (Annual)$1.61

P/B Ratio1.50x

P/B Ratio (Quarterly)1.30x

Net Income / Employee (Annual)$-117,200

EV / Revenue (TTM)2.30x

Net Interest Coverage (TTM)-6.78x

ROA (TTM)-1.12%

EV / EBITDA (TTM)12.70x

EPS Incl Extra (Annual)$-3.00

Current Ratio (Annual)1.38x

Quick Ratio (Quarterly)0.83x

3-Month Avg Trading Volume9.45M

52-Week Price Return84.70%

EV / Free Cash Flow (Annual)18.31x

Revenue / Employee (TTM)$491,200

Tangible BV / Share (Quarterly)$0.51

P/S Ratio (Annual)1.50x

Asset Turnover (Annual)0.38x

52-Week High$18.66

Operating Margin (5Y Avg)-1.79%

EPS Excl Extra (Annual)$-3.00

CapEx CAGR (5Y)-7.35%

Tangible BV CAGR (5Y)29.84%

26-Week Price Return34.11%

Quick Ratio (Annual)0.70x

13-Week Price Return7.89%

Total Debt / Equity (Annual)0.98x

Current Ratio (Quarterly)1.58x

Enterprise Value$33.89B

Revenue / Share Growth (5Y)-9.28%

Asset Turnover (TTM)0.40x

Book Value / Share Growth (5Y)-7.64%

Revenue / Employee (Annual)$476,700

Inventory Turnover (Annual)2.20x

Pretax Margin (Annual)-25.63%

Cash / Share (Annual)$1.24

3-Month Return Std Dev27.67%

Gross Margin (5Y Avg)40.95%

Net Income / Employee (TTM)$-13,700

EBITDA CAGR (5Y)-56.10%

EBITDA Interim CAGR (5Y)-12.31%

ROE (Last FY)-23.89%

Net Interest Coverage (Annual)-0.38x

EPS Basic Excl Extra (Annual)$-3.00

P/FCF (TTM)11.82x

Receivables Turnover (TTM)4.98x

EV / Free Cash Flow (TTM)18.70x

Total Debt / Equity (Quarterly)0.94x

EPS Incl Extra (TTM)$-0.36

Receivables Turnover (Annual)5.44x

ROI (TTM)-1.42%

P/S Ratio (TTM)1.45x

Pretax Margin (5Y Avg)-2.99%

Revenue / Share (Annual)$12.21

Tangible BV / Share (Annual)$1.31

Forward P/E6.55x

Free OCF CAGR (5Y)27.44%

Price vs S&P 500 (52W)69.17%

Year-to-Date Return49.84%

5-Day Price Return6.36%

EPS Normalized (Annual)$-3.00

ROA (5Y Avg)-1.80%

Net Profit Margin (Annual)-24.58%

Month-to-Date Return5.28%

Cash Flow / Share (TTM)$3.97

EBITD / Share (Annual)$0.03

Operating Margin (Annual)-19.34%

LT Debt / Equity (Annual)0.85x

P/CF (TTM)9.19x

ROI (5Y Avg)-2.33%

LT Debt / Equity (Quarterly)0.81x

EPS Basic Excl Extra (TTM)$-0.36

P/TBV (Quarterly)31.69x

Payout Ratio (Annual)28.47%

P/B Ratio (Annual)0.97x

Dividend / Share (TTM)$0.48

Inventory Turnover (TTM)2.15x

Pretax Margin (TTM)-4.49%

Book Value / Share (Annual)$12.78

Price vs S&P 500 (13W)5.21%

Dividend Yield (TTM)2.60%

Beta0.89x

P/FCF (Annual)11.58x

Revenue / Share (TTM)$12.67

ROE (TTM)-2.79%

52-Week Low$9.92

vGradeB

gGradeC

mGradeA

vgmGradeB

VTRS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.60	$0.69	+15.04%(+$0.09)
Q1 2026	May 7, 2026	$0.50	$0.59	+17.54%(+$0.09)
Q4 2025	Feb 26, 2026	$0.53	$0.57	+7.39%(+$0.04)
Q3 2025	Nov 6, 2025	$0.62	$0.67	+8.52%(+$0.05)
Q2 2025	Aug 7, 2025	$0.56	$0.62	+11.55%(+$0.06)

VTRS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.83

3.82

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Viatris Inc. Common Stock

Viatris is a globally diversified pharmaceutical company formed in November 2020 through the merger of Pfizer's Upjohn division and Mylan, establishing itself as one of the world's largest generic drug manufacturers serving over 165 countries. The company generates approximately 60% of revenues from established pharmaceutical products including Lipitor, Norvasc, Lyrica, and Viagra, while the remaining 40% comes from generic drugs and biosimilars. Viatris operates across over 10 therapeutic areas, with strategic focus on dermatology, ophthalmology, and gastroenterology for future growth.